AdvaMed Releases Statement Following Riots at U.S. Capitol
Following a violent day in which rioters gathered to protest the presidential election results and stormed the U.S. Capitol building (resulting in four deaths) AdvaMed President and CEO Scott Whitaker released a statement condemning these actions:
“Today’s violence at the U.S. Capitol does not represent who we are or who we should be as a nation. We condemn it. In this country, we settle our political differences by passionately but peacefully seeking changes in policy through the process established by our Constitution. The presidential election – certified by the states, the Electoral College, and the courts – will be ratified by Congress. It is now time to move forward together, as one nation, and build upon what unites us. We look forward to working with President Biden and the new Congress to advance policies that save and improve the lives of the patients we serve.”
Related Articles
-
AdvaMed has filed comments with the EPA regarding proposed regulations of ethylene oxide and their impact on patient care.
-
Veeva Vault CRM for Medtech is a unified customer relationship management (CRM) and content management application built for medtech sales teams, key account managers and medical affairs professionals.
-
Cybersecurity, remanufacturing of devices and chemical analysis for biocompatibility assessment of medical devices are among the topics FDA plans to address through draft and final guidances in 2023.
-
Medtronic will invest up to $75 million and immediately begin co-promotion of CathWorks’ FFRangio System for the noninvasive diagnosis of CAD in the U.S., Europe and Japan, where it is commercially available.
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.